All In Biotech

Drug Trial Radar · NCT02938299

Neoadjuvant L19IL2/L19TNF- Pivotal Study

A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 214 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

214

Planned (sponsor's estimate)

Start

Jul 1, 2016

Primary completion

Oct 2024

Study completion Dec 2028

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Oct 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.

Conditions

  • Malignant Melanoma

Interventions

  • L19IL2 + L19TNFDrug

    Mixture of L19IL2 and L19TNF once weekly

  • SurgeryProcedure

    Surgical resection of melanoma tumor lesions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survival (RFS) rateTime frame: 1 year after randomization

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Hôpital de la Timone

    Marseille, France

  • Hôpital Universitaire de Nantes

    Nantes, France

  • Institut Gustave Roussy

    Villejuif, France

  • Klinik für Dermatologie und Allergologie, Universitätsklinikum Augsburg

    Augsburg, Germany

  • Klinik für Dermatologie, Medizinische Fakultät Universitätsklinikum Essen

    Essen, Germany

  • Klinik und Polyklinik für Dermatologie, Universitätsklinikum Regensburg

    Regensburg, Germany

  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

    Dresden, Dresden, Germany

  • Hauttumorzentrum Hannover (HTZH)

    Hanover, Hannover, Germany

  • Heidelberg University Hospital

    Heidelberg, Heidelberg, Germany

  • Kiel University Hospital

    Kiel, Kiel, Germany

  • Leipzig University Hospital

    Leipzig, Leipzig, Germany

  • Charité Campus Mitte (CCM)

    Berlin, State of Berlin, Germany

  • Tübingen University Hospital

    Tübingen, Tübingen, Germany

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Naples, Italy

  • AOU Senese

    Siena, Italy

  • ASUGI Trieste

    Trieste, Italy

  • AOU Città della Salute e della Scienza

    Turin, Italy

  • IRCCS A.O.U. San Martino - IST

    Genova, Genova, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Milan, Italy

  • Istituto Oncologico Veneto, IRCCS

    Padova, Padova, Italy

  • Medgart Centrum Medyczne

    Gdansk, Poland

  • Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.